GSK plc (NYSE:GSK) Shares Bought by Mirador Capital Partners LP

Mirador Capital Partners LP increased its position in GSK plc (NYSE:GSK) by 5.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,733 shares of the pharmaceutical company’s stock after acquiring an additional 722 shares during the period. Mirador Capital Partners LP’s holdings in GSK were worth $632,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of GSK. Fisher Asset Management LLC raised its stake in shares of GSK by 10.8% during the fourth quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock valued at $558,330,000 after purchasing an additional 1,465,165 shares in the last quarter. Primecap Management Co. CA lifted its stake in shares of GSK by 0.3% in the 4th quarter. Primecap Management Co. CA now owns 12,089,370 shares of the pharmaceutical company’s stock worth $448,032,000 after acquiring an additional 30,600 shares during the period. Royal Bank of Canada boosted its holdings in shares of GSK by 5.1% in the third quarter. Royal Bank of Canada now owns 8,079,897 shares of the pharmaceutical company’s stock valued at $292,896,000 after acquiring an additional 389,871 shares in the last quarter. Morgan Stanley increased its stake in shares of GSK by 2.1% during the third quarter. Morgan Stanley now owns 7,551,555 shares of the pharmaceutical company’s stock valued at $273,744,000 after acquiring an additional 156,480 shares during the period. Finally, Provident Trust Co. raised its holdings in GSK by 53.6% during the fourth quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock worth $137,746,000 after purchasing an additional 1,297,385 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GSK has been the subject of a number of research analyst reports. Citigroup raised shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. The Goldman Sachs Group assumed coverage on shares of GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price objective for the company. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Finally, Berenberg Bank raised GSK to a “strong-buy” rating in a research report on Thursday, June 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $47.00.

GSK Stock Down 0.3 %

GSK stock opened at $38.38 on Tuesday. GSK plc has a twelve month low of $33.67 and a twelve month high of $45.92. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.58 and a current ratio of 0.87. The firm has a market cap of $79.54 billion, a PE ratio of 13.90, a P/E/G ratio of 1.16 and a beta of 0.64. The firm’s 50 day moving average price is $42.51 and its two-hundred day moving average price is $41.23.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. The business had revenue of $9.34 billion for the quarter, compared to the consensus estimate of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. On average, research analysts predict that GSK plc will post 4.11 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be issued a dividend of $0.3762 per share. This represents a $1.50 annualized dividend and a dividend yield of 3.92%. This is a positive change from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. GSK’s payout ratio is currently 53.26%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.